Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Preventing the common cold
Dear Readers,
As we await our vaccination date for COVID-19, the thought of coming down with a cold almost seems harmless. Yet, the common cold is responsible for 150 million missed workdays each year in the United States. Many of us will head to the nutrition supplement aisle in an attempt to ward off these nasty viruses, but do these supplements really work? We investigated four of them, and this is what we found:
• Elderberry: In a study of 312 air travelers, those using elderberry had an average of a 2-day shorter duration of the cold and experienced fewer symptoms (1). More extensive studies are needed to confirm these results. Remember, several studies are needed before scientific value can be determined.
The opioid crisis and HIV in the USA: deadly synergies thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Dear Readers, As we await our vaccination date for COVID-19, the thought of coming down with a cold almost seems harmless. Yet, the common cold is responsible for 150 million missed workdays each year in the United States. Many of us will head to the nutrition supplement aisle in an attempt to ward off these nasty viruses, but do these supplements really work? We investigated four of them, and this is what we found:
1. Elderberry: In a study of 312 air travelers, those using elderberry had an average of a two-day shorter duration of the cold and experienced fewer symptoms (1). More extensive studies are needed to confirm these results. Remember, several studies are needed before scientific value can be determined.
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
February 10, 2021 18:42 ET | Source: Mesoblast Limited Mesoblast Limited Melbourne, AUSTRALIA
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments. The results indicate that a single injection of rexlemestrocel-L may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic